Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

CHMP Recommends Bayer Drug for Gastrointestinal Stromal Tumors

June 27, 2014 10:54 am | News | Comments

The oncology compound regorafenib (Stivarga) from Bayer has been recommended for approval by the European Committee for Medicinal Products for Human Use for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors. Read more...

TOPICS:

Lilly-BI Compound is First Biosimilar Insulin Backed by CHMP

June 27, 2014 10:41 am | News | Comments

The investigational compound LY2963016, a new insulin glargine product from Eli Lilly and Co. and Boehringer Ingelheim for the treatment of type 1 and type 2 diabetes, is the first biosimilar insulin recommended for approval in the EU. Read more...

TOPICS:

Prosensa Snags $200,000 Research Grant from PPMD

June 27, 2014 10:26 am | News | Comments

Prosensa announced that the company's vice president of drug discovery, Dr. Judith van Deutekom, has been awarded a $200,000 research grant from Parent Project Muscular Dystrophy to fund the development of a multi exon-skipping strategy for exons 10-30 of the dystrophin gene. Read more...

TOPICS:
Advertisement

Some Aggressive Cancers May Respond to Anti-Inflammatory Drugs

June 26, 2014 7:25 pm | News | Comments

New research raises the prospect that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs used to treat rheumatoid arthritis. Read more...                   

TOPICS:

BI’s Pradaxa Antidote Gets FDA Breakthrough Status

June 26, 2014 2:12 pm | News | Comments

Boehringer Ingelheim Pharmaceuticals Inc. announced that the FDA has granted Breakthrough Therapy Designation to idarucizumab, an investigational fully humanized antibody fragment, or Fab, being studied as a specific antidote for Pradaxa. Read more...

TOPICS:

AbbVie Initiates New Veliparib Trial in Advanced Breast Cancer

June 26, 2014 2:01 pm | News | Comments

AbbVie announced the initiation of a Phase 3 clinical trial of its investigational compound, veliparib, when added to carboplatin and paclitaxel, two chemotherapeutic medicines, in patients with advanced breast cancer. Read more...      

TOPICS:

Low-dose Aspirin Use May Lower Pancreatic Cancer Risk

June 26, 2014 1:17 pm | News | Comments

The longer a person took low-dose aspirin, the lower his or her risk for developing pancreatic cancer, according to a new study. Men and women who took low-dose aspirin regularly had 48 percent reduction in their risk for developing pancreatic cancer. Read more...

TOPICS:

FDA Warns of Allergic Reactions With Acne Products

June 26, 2014 1:05 pm | by Matthew Perrone, AP Health Writer | News | Comments

Federal health officials are warning consumers who use popular anti-acne treatments about rare but potentially deadly allergic reactions that can cause swelling of the face and difficulty breathing. Read more...            

TOPICS:
Advertisement

Flu Spray Better Than Shots for Young Kids

June 26, 2014 12:57 pm | by Mike Stobbe, AP Medical Writer | News | Comments

When it comes to flu vaccines, a federal panel says a squirt in the nose is better than a shot in the arm for young children. The advisory panel voted Wednesday to advise doctors that FluMist nasal spray is a bit better at preventing flu in healthy young kids. Read more...

TOPICS:

Human Longevity Supports Innovation to Advance Treatment of Cancer, Other Diseases

June 26, 2014 11:10 am | News | Comments

Human Longevity Inc., a genomics and cell therapy-based diagnostic and therapeutic company focused on extending the healthy, high performance human life span, called on physicians, the insurance industry and political leaders to support promising new avenues of medical discovery on behalf of patients with life-threatening diseases including cancer. Read more...

TOPICS:

MicroRNA Offers Target for Osteoporosis and Bone Metastases Drugs

June 26, 2014 11:04 am | News | Comments

UT Southwestern cancer researchers have identified a promising molecule - miR-34a from a family of small molecules called microRNAs - that blocks bone destruction and, therefore, could provide a potential therapeutic target for osteoporosis and bone metastases of cancer. Read  more...

TOPICS:

G20 World Brain Mapping and Therapeutics Initiative Partners with EU Human Brain Project

June 26, 2014 10:57 am | News | Comments

According to the World Health Organization's large-scale studies, about a third of the adult worldwide population suffer from a mental disorder such as depression, anxiety and schizophrenia, and European Union, China, India, Japan and Australia are not immune from the high cost of healthcare despite having 100% government insurance. Read more...

TOPICS:

Researchers Closer to Helping Millions Battle Lung Cancer

June 26, 2014 10:51 am | News | Comments

Researchers at the University of Louisville, led by Chi Li, assistant professor of medicine, have uncovered a cadre of small molecules that tell certain proteins to kill lung cancer cells and have published their finding in Molecular and Cellular Biology. Read more...

TOPICS:

Abbvie Cites Tax Break as a Shire Deal Motivator

June 26, 2014 10:44 am | by Tom Murphy, AP Business Writer | News | Comments

U.S. drugmaker AbbVie laid out the reasoning behind their unsolicited, cash-and-stock offer, noting a compelling tax break behind its roughly $46 billion bid to buy British counterpart Shire, and it expects the deal to expand Shire's global reach as well. Read more...

TOPICS:

FDA Committee Rejects Cancer Drug Accelerated Approval

June 26, 2014 10:37 am | News | Comments

AstraZeneca announced that the FDA Oncologic Drugs Advisory Committee voted 11 to 2 that current evidence does not support an accelerated approval for use of olaparib as a maintenance treatment for women with platinum-sensitive relapsed ovarian cancer with germline BRCA (gBRCA) mutation, and who are in complete or partial response to platinum-based chemotherapy. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading